U.S. flag

An official website of the United States government

NM_000546.6(TP53):c.145G>A (p.Asp49Asn) AND Li-Fraumeni syndrome

Germline classification:
Benign (3 submissions)
Last evaluated:
Aug 5, 2024
Review status:
3 stars out of maximum of 4 stars
reviewed by expert panel
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000540357.18

Allele description [Variation Report for NM_000546.6(TP53):c.145G>A (p.Asp49Asn)]

NM_000546.6(TP53):c.145G>A (p.Asp49Asn)

Gene:
TP53:tumor protein p53 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
17p13.1
Genomic location:
Preferred name:
NM_000546.6(TP53):c.145G>A (p.Asp49Asn)
HGVS:
  • NC_000017.11:g.7676224C>T
  • NG_017013.2:g.16327G>A
  • NM_000546.6:c.145G>AMANE SELECT
  • NM_001126112.3:c.145G>A
  • NM_001126113.3:c.145G>A
  • NM_001126114.3:c.145G>A
  • NM_001126118.2:c.28G>A
  • NM_001276695.3:c.28G>A
  • NM_001276696.3:c.28G>A
  • NM_001276760.3:c.28G>A
  • NM_001276761.3:c.28G>A
  • NP_000537.3:p.Asp49Asn
  • NP_000537.3:p.Asp49Asn
  • NP_001119584.1:p.Asp49Asn
  • NP_001119585.1:p.Asp49Asn
  • NP_001119586.1:p.Asp49Asn
  • NP_001119590.1:p.Asp10Asn
  • NP_001263624.1:p.Asp10Asn
  • NP_001263625.1:p.Asp10Asn
  • NP_001263689.1:p.Asp10Asn
  • NP_001263690.1:p.Asp10Asn
  • LRG_321t1:c.145G>A
  • LRG_321:g.16327G>A
  • LRG_321p1:p.Asp49Asn
  • NC_000017.10:g.7579542C>T
  • NM_000546.4:c.145G>A
  • NM_000546.5(TP53):c.145G>A
  • NM_000546.5:c.145G>A
  • P04637:p.Asp49Asn
  • p.D49N
Protein change:
D10N
Links:
UniProtKB: P04637#VAR_044572; dbSNP: rs587780728
Molecular consequence:
  • NM_000546.6:c.145G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001126112.3:c.145G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001126113.3:c.145G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001126114.3:c.145G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001126118.2:c.28G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001276695.3:c.28G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001276696.3:c.28G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001276760.3:c.28G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001276761.3:c.28G>A - missense variant - [Sequence Ontology: SO:0001583]
Observations:
3

Condition(s)

Name:
Li-Fraumeni syndrome (LFS)
Synonyms:
Sarcoma family syndrome of Li and Fraumeni
Identifiers:
MONDO: MONDO:0018875; MedGen: C0085390; OMIM: PS151623

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000629784Labcorp Genetics (formerly Invitae), Labcorp
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Likely benign
(Nov 26, 2025)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

SCV001142537ClinGen TP53 Variant Curation Expert Panel, ClinGen
reviewed by expert panel

(ClinGen TP53 ACMG Specifications TP53 V2.0.0)
Benign
(Aug 5, 2024)
germlinecuration

Citation Link,

SCV004823846All of Us Research Program, National Institutes of Health
criteria provided, single submitter

(ACMG Guidelines, 2015)
Likely Benign
(Feb 5, 2024)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknown3not providednot provided108544not providedclinical testing, curation

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group, Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240. doi: 10.1038/s41436-019-0624-9..

PubMed [citation]
PMID:
28492532
PMCID:
PMC5632818

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee.

Genet Med. 2015 May;17(5):405-24. doi: 10.1038/gim.2015.30. Epub 2015 Mar 5.

PubMed [citation]
PMID:
25741868
PMCID:
PMC4544753

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV000629784.11

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From ClinGen TP53 Variant Curation Expert Panel, ClinGen, SCV001142537.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedcurationnot provided

Description

The NM_000546.6 :c.145G>A variant in TP53 is a missense variant predicted to cause substitution of aspartic acid by asparagine at amino acid 49 (p.Asp49Asn). This variant has been observed in at least 8 heterozygous unrelated females from the same data source with no personal history of cancer prior to age 60 years and no personal history of sarcoma at any age (BS2; ClinVar SCV: SCV000216702.6). This variant has an allele frequency of 0.0000111525 (18/1613988 alleles) across gnomAD v4.1.0 (after removing low AB alleles likely to represent CHIP contamination and recalculating total allele frequency) which is lower than the Clingen TP53 VCEP threshold (<0.00003) for PM2_Supporting, and therefore meets this criterion (PM2_Supporting). In vitro assays performed in yeast and/or human cell lines showed functional transactivation and retained growth suppression activity indicating that this variant does not impact protein function (BS3; PMIDs: 12826609, 29979965, 30224644). Computational predictor scores (BayesDel = -0.232; Align GVGD Class C0) are below the recommended thresholds (BayesDel ≤ -0.008 and an Align GVGD Class ≤ 55), evidence that does not predict a damaging effect on TP53 via protein change. SpliceAI predicts that the variant has no impact on splicing (BP4_Moderate). In summary, this variant meets the criteria to be classified as Benign for Li Fraumeni Syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen TP53 VCEP: BS2, PM2_Supporting, BS3, BP4_Moderate. (Bayesian Points: -9; VCEP specifications version 2.0; 7/24/2024)

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From All of Us Research Program, National Institutes of Health, SCV004823846.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not provided3not providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknown108544not providednot provided3not providednot providednot provided

Last Updated: Apr 12, 2026

Modify your search Search (all fields optional) Clear all
Advanced Search